|
GB201720279D0
|
|
Anticancer compounds
|
|
GB201715011D0
|
|
Floxuridine synthesis
|
|
GB201713914D0
|
|
Combination therapy
|
|
GB201713916D0
|
|
Treatment regimens
|
|
GB201709471D0
|
|
Diastereoselective synthesis of hosphate derivatives
|
|
GB201609770D0
|
|
Combination therapy
|
|
GB201609601D0
|
|
Phosphoramidate compounds
|
|
GB201522771D0
|
|
Crystalline form of a phosphate derivative
|
|
GB201522764D0
|
|
Formulations of phosphate derivatives
|
|
KR20170087465A
|
|
New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
|
|
GB201519316D0
|
|
Chemical compounds
|
|
CN106795198A
|
|
Method for preparing gemcitabine [phenyl (benzyloxy L alaninyls)] phosphate
|
|
SG11201608809RA
|
|
Formulation comprising a gemcitabine-prodrug
|
|
KR20170043479A
|
|
Gemcitabine prodrugs
|
|
GB201421211D0
|
|
Chemical compounds
|
|
GB201417644D0
|
|
Method of separating phosphate diastereoisomers
|
|
GB201417646D0
|
|
Formulations of phosphate derivatives
|
|
GB201411253D0
|
|
Prodrug
|
|
CN104974206A
|
|
Phosphoramidate Derivatives Of 5-Fluoro-2'-Deoxyuridine For Use In The Treatment Of Cancer
|
|
GB201105660D0
|
|
Chemical compounds
|
